Altay, Melek Firat http://orcid.org/0000-0002-8174-5631
Kumar, Senthil T. http://orcid.org/0000-0002-4322-3963
Burtscher, Johannes http://orcid.org/0000-0002-2889-0151
Jagannath, Somanath
Strand, Catherine
Miki, Yasuo
Parkkinen, Laura http://orcid.org/0000-0002-3392-8564
Holton, Janice L.
Lashuel, Hilal A. http://orcid.org/0000-0001-7682-8320
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson’s Research (020698)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31ER30_186198)
Article History
Received: 21 June 2023
Accepted: 14 November 2023
First Online: 7 December 2023
Change Date: 11 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41531-024-00634-0
Competing interests
: H.A.L. is the co-founder and chief scientific officer of ND BioSciences, Epalinges, Switzerland, a company that develops diagnostics and treatments for neurodegenerative diseases (NDs) based on platforms that reproduce the complexity and diversity of proteins implicated in NDs and their pathologies. H.A.L. has received funding from industry to support research on neurodegenerative diseases, including Merck Serono, UCB, and Abbvie. These companies had no specific role in the conceptualization, preparation, and decision to publish this manuscript. H.A.L. is the associate editor of <i>npj Parkinson’s Disease</i>. H.A.L. was not involved in the journal’s review of, or decisions related to, this manuscript. M.F.A., S.T.K., J.B., S.J., C.S., Y.M., L.P. and J.L.H. declare no competing interests.